Immunotherapy
VIDEO: Dual immunotherapy outperforms monotherapy in metastatic colorectal cancer
In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.
AK104 with concurrent radiotherapy shows efficacy in locally advanced cervical cancer
The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical cancer, according to data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Two-drug regimen active in advanced endometrial cancer
A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer showed.
Physical function predicts outcomes after CAR-T
Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort study.
Siltuximab reduces severity of cytokine release syndrome, ICANS after CAR T-cell therapy
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, according to findings published in Blood Advances.
Response to peanut patch treatment increases through 60 months
SAN DIEGO — Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV Technologies increased from 12 months through 60 months, according to an abstract presented here.
Chart review supports expansion of subcutaneous immunotherapy, oral food challenges
SAN DIEGO — A retrospective chart review of patients with allergy who participated in subcutaneous immunotherapy and oral food challenges suggested that these therapies should be expanded, according to a pair of posters presented here.
‘Global problem’: Numerous factors, biases contribute to overtreatment at end of life
Nathan I. Cherny, MD, has worked all around the world.
‘Lose-lose-lose’ scenario: ASCO seeks reduced out-of-pocket costs for cancer care
Out-of-pocket costs like deductibles and copays deter people with cancer from complying with treatment.
Regimen may become new standard for relapsed/refractory diffuse large B-cell lymphoma
The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with relapsed or refractory diffuse large B-cell lymphoma, according to results of a phase 1b/phase 2 trial.